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Background: Acetaminophen (APAP) is a commonly used analgesic. However, its use is associated with drug-induced
liver injury (DILI). It is a prominent cause of acute liver failure, with APAP hepatotoxicity far exceeding other causes of
acute liver failure in the United States. In order to improve its safe use this study aimed to identify individuals at risk
for DILI prior to drug treatment by searching for non-genetic serum markers in healthy subjects susceptible to
APAP-induced liver injury (AILI).
Methods: Healthy volunteers (n = 36) received either placebo or acetaminophen at the maximum daily dose of 4 g
for 7 days. Blood samples were taken prior to and after APAP treatment. Serum proteomic profiling was done by
2D SDS-PAGE and matrix-assisted laser desorption/ionization-time of flight-mass spectrometry. Additionally, the
proteins C-reactive protein, haptoglobin and hemopexin were studied by quantitative immunoassays.
Results: One-third of study subjects presented more than four-fold increased alanine transaminase activity to
evidence liver injury, while serum proteomics informed on 20 proteins as significantly regulated. These function
primarily in acute phase and immune response. Pre-treatment associations included C-reactive protein,
haptoglobin isoforms and retinol binding protein being up to six-fold higher in AILI susceptible individuals,
whereas alpha1-antitrypsin, serum amyloid A, kininogen and transtyretin were regulated by nearly five-fold in AILI
responders. When compared with published findings for steatohepatitis and cases of hepatocellular, cholestatic
and mixed DILI, 10 proteins were identified as uniquely associated with risk for AILI, including plasminogen.
Notably, this zymogen facilitates macrophage chemotactic migration and inflammatory response as reported for
plasminogen-deficient mice shown to be resistant to APAP hepatotoxicity. Finally, analysis of a publicly available
database of gene expression profiles of cultures of human hepatocytes treated with drugs labeled as no- (n = 8),
low- (n = 45) or most-DILI-concern (n = 39) confirmed regulation of the identified biomarkers to demonstrate utility
in predicting risk for liver injury.
Conclusions: The significant regulation of acute phase reactants points to an important link between AILI and the
immune system. Monitoring of serum acute phase reactants prior to drug treatment may contribute to prevention
and management of AILI, and may also be of utility for other drugs with known liver liabilities.* Correspondence: Borlak.Juergen@mh-hannover.de
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Drug-induced liver injury (DILI) is a major reason for
drug failures in clinical trials, for withdrawal from the
market or 'black box warnings' issued by the US Food
and Drug Administration [1,2]. More than 1,000 drugs
are suspected to cause liver injury in humans [3,4] and
DILI accounts for more than 50% of acute liver failures
(ALFs), with acetaminophen (APAP) hepatotoxicity far
exceeding other causes of ALF in the United States [5].
It is perplexing that despite vigorous and extensive safety
testing, animal studies fail to identify about 50% of drugs
causing liver toxicity in clinical trials [6]. A major reason
for drug withdrawal from the market or black box warn-
ings is dose and treatment duration, particularly at pre-
scribed daily doses of 100 mg or greater [7-9]. However,
many drugs are safe at daily doses of 100 mg or higher
with little or no risk of hepatotoxicity. A refined ap-
proach is therefore needed to predict risk for DILI.
Importantly, with idiosyncratic DILI neither dose nor
duration can be used to reliably predict hepatotoxicity.
Idiosyncratic DILI is host dependent but not clearly dose
related and frequently unrelated to the pharmacology of
the drug; nonetheless, it is the most common reason for
regulatory action and drug failures in clinical trials. Its
pathologic mechanism is far from clear but may result
from metabolic and or immune-mediated responses,
with DILI histopathology revealing a broad spectrum of
morphological presentations that are also common to
other acute or chronic liver diseases.
Identifying individuals at risk for DILI prior to drug
treatment would greatly improve drug safety and would
have major implications for clinical practice. Although
genetic associations with DILI susceptibility have been
reported, none have yet been strong enough to be useful
for managing DILI in the clinic. Indeed, in a most recent
publication the DILI network reported the limited con-
tribution of common genetic variants to risk for DILI
for more than 200 drugs based on genome-wide associ-
ation studies of 783 individuals who experienced signifi-
cant liver injury [10].
Identifying non-genetic factors to predict individuals
at risk for DILI prior to drug treatment would be a
major breakthrough in its prevention. Furthermore,
enabling outpatient monitoring of risk for DILI with a
simple non-invasive test - measurement of biomarkers
in either sputum or urine - would enable out-patients to
monitor their risk for DILI and thus would help defeat
the current limitations in post-marketing surveillance,
with pharmacovigilance being frequently presumptive
and primarily confined to signal detection.
This study aimed to identify non-genetic biomarkers
to predict DILI susceptibility by serum proteomic
profiling of healthy subjects prior to and after treatment
with the maximum acceptable dose of APAP given inquarterly portions per day for 7 days. The serum pro-
teins identified inform on the importance of acute phase
reactants in predisposing individuals at risk to DILI.Methods
Ethical statement
The study was approved by the ethics review board of
the General Clinical Research Center at the University of
North Carolina Hospitals, USA and was therefore
performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki and its later
amendments. The approval was obtained by Dr Paul
Watkins. Participants gave written informed consent be-
fore entering the study and were housed in clinical re-
search facilities for the entire study.Study design
The original study protocol is described in detail in
[11,12] and consisted of a two-center, randomized, single-
blind (participants were blinded to treatment assign-
ment), placebo-controlled, longitudinal design. Eligible
participants were healthy men and women volunteers of
non-childbearing potential aged between 18 and 45
years. Participants were considered to be healthy based
on medical history, physical examination, electrocardio-
gram results and clinical laboratory measures (includ-
ing negative urine drug screen, hepatitis B surface
antigen and hepatitis C antibody results). No partici-
pants entered the study on concomitant medications.
Race/ethnicity was self-reported; country of origin was
not recorded.
Details regarding the study subjects are given in
Additional file 1; each participant received either pla-
cebo or APAP. A total of n = 11 subjects on placebo
(CB26-06 lot 2) and n = 25 receiving 1 g/qid APAP
(4 g in total per day) were selected, of which n = 12
presented alanine transaminase (ALT) elevations of
more than four-fold, on average, while n = 13 did not re-
spond to this daily treatment for 7 days. No participant
characteristics distinguished responders from non-
responders, including urine metabolomic studies prior
to dosing as recently reported [12].Preparation of serum samples
Blood serum samples from n = 36 participants were
analyzed. After clotting for 30 minutes at room tempera-
ture, the blood was centrifuged at 2,000 rpm for 15
minutes. Hemolysis was not observed. The resultant
supernatants were removed, frozen immediately in liquid
nitrogen and stored at -80°C until further analysis. The
protein concentration in serum was determined by the
Bradford assay and ranged from 140 to 250 μg/μl.
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Removal of high abundant proteins
Albumin and IgG were depleted in human serum using
SpinTrap™ columns (GE Healthcare, Uppsala, Sweden).
Columns are prepacked with a mixture of anti-HSA
Sepharose High Performance and Protein G Sepharose
High Performance. The mixed media consists of 34 μm
high cross-linked agarose beads with covalently immobi-
lized affinity ligands. Depletion columns were applied
according to the manufacturer’s instructions. A binding
buffer consisting of 20 mM sodium phosphate, 0.15 M
sodium chloride, pH 7.4 was used. Undiluted human
serum (50 μl) was diluted with binding buffer to a final
volume of 100 μl before application to the column. The
protein concentration in depleted serum determined by
the Bradford test ranged from 3.2 to 9.2 μg/μl. Samples
were purified thereafter using the ReadyPrep™ 2D
Cleanup kit (BioRad, Hercules, CA, USA) to improve
isoelectric focusing (IEF) resolution by removing salts,
contaminants, detergents, lipids and other compounds.
One- and two-dimensional SDS-PAGE
First dimension Serum proteins were separated by IEF
and precast immobilized pH gradient (IPG) strips of pH
3 to 10 (non-linear gradient; 170 × 3 × 0.5 mm, BioRad)
and pH 4 to 7 (linear gradient; 170 × 3 × 0.5 mm,
BioRad) were used. Each sample was analyzed in dupli-
cate. We diluted 300 μg in a lysis buffer containing
2 mol/l thiourea, 5 mol/l urea, 40 mmol/l Tris, 4%
CHAPS, 0.5% BioLyte 3-10 (BioRad), and 100 mmol/l
dithiothreitol, resulting in a total volume of 300 μl per
strip. Focused IPG strips were rehydrated at 50 V for
12 h. IEF was performed at 20°C with a maximum volt-
age of 10 kV and a maximum current of 50 μA per strip.
After IEF, IPG strips were equilibrated in 10 ml reducing
buffer (2% dithiothreitol in 10 ml equilibration buffer
containing 6 mol/l urea, 30% glycerine, 2% SDS, 0.05
mol/l Tris-HCl, pH 8.8 and 0.5% bromophenol blue) for
15 minutes, followed by equilibration in 10 ml alkylation
buffer (4% iodoacetamide and 0.5% bromophenol blue in
10 ml equilibration buffer) for 15 minutes.
Second dimension SDS-PAGE was performed in a
Protean-plus Dodeca™ Cell (BioRad) using self-cast poly-
acrylamide gels (200 × 205 × 1.5 mm; 12%T). Gels were
run in parallel in 0.025 mol/l Tris/0.192 mol/l glycine/
0.1% SDS cooled externally to 10°C with a constant volt-
age of 70 V for approximately 16 h, followed by 200 V
until the bromophenol blue dye reached the bottom of
the gel. Unstained protein standards (BioRad) were used
for calibration of Mr and pI.
Staining
Two-dimensional gels were fixed overnight in 500 ml
30% ethanol/2% phosphoric acid and washed twice for30 minutes each in 500 ml 2% phosphoric acid. Equili-
bration was done in 500 ml 2% phosphoric acid/18%
ethanol/15% ammonium sulfate for 30 minutes there-
after. Colloidal Coomassie Brilliant Blue (CBB) staining
of proteins was performed by addition of 5 ml staining
solution (2% CBB G250, Roth, Karlsruhe, Germany) to
500 ml of equilibration solution. Gels were stained for
72 h and washed once with 500 ml deionized water for
5 minutes thereafter.
Imaging
Gels were scanned as TIFF images with the 16-bit
Expression 10000 XL™ (Epson, Nagano, Japan) operating
in transmitted light mode. PDQuest™ software (version
8.0.1.55, BioRad) was used for detection of spots, quanti-
fication and comparison of two-dimensional protein pro-
files. Background and vertical streaks were removed
from each gel image; spots were digitized by Gaussian
fit. To quantify protein spots, a match set of all gels was
made and the absorbance of individual protein spots
from two-dimensional gels was measured. Total density
in the gel image was used for normalization of spots. In
this method, the raw quantity of each spot in a member
gel is divided by the total intensity value of all the
pixels in the image. This model assumes that the total
density of an image (that is, background density plus
spot intensity) will be relatively consistent from gel to
gel. Student’s t-test and Mann-Whitney signed-rank
test were used for analysis of protein expression. A
probability of P < 0.05 was considered statistically sig-
nificant. Differentially regulated spots were excised
and transferred to 96-well microtiter plates (Thermo,
Waltham, MA, USA) by the EXQuest™ spot cutter (BioRad)
for further identification by mass spectrometry.
Matrix-assisted laser desorption/ionization-time of
flight-mass spectrometry
Each of the CBB-stained gel plugs was washed twice
with 15 μl ammonium hydrogencarbonate solution (100
mmol/l) and then dehydrated twice with 15 μl aceto-
nitrile. Proteins were digested with a total of 80 ng tryp-
sin (sequencing grade, Promega, Madison, WI, USA) per
gel plug at 37°C for 4 h. Resulting peptides were
extracted with 1% trifluoroacetic acid in an ultrasonic
bath (Sonorex, Super RK 514 BH, Bandelin, Berlin,
Germany) for 10 minutes.
The peptide extracts (2 μl) were manually spotted onto
a 600 μm/384 well AnchorChip™ sample target (Bruker
Daltonics, Bremen, Germany) and dried at room
temperature. The matrix-assisted desorption/ionization
(MALDI) target was covered with a thin layer of alpha-
cyano-4-hydroxycinnamic acid matrix dissolved in 97%
acetone/3% trifluoroacetic acid 0.1% to saturation. To
enable tandem mass spectrometry measurement, matrix
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nol/30% acetone/10% trifluoroacetic acid 1%. MALDI
mass spectra were recorded using an Ultraflex II time of
flight (TOF)/TOF mass spectrometer (Bruker Daltonics)
equipped with a 384-sample scout source. An external
peptide calibration standard containing the following
fragments was used to calibrate the instrument: angio-
tensin II ([M +H]+ 1046.54); angiotensin I ([M +H]+
1296.68); substance P ([M +H]+ 1347.74); bombesin
([M +H]+ 1619.82); ACTH clip 1-17 ([M +H]+ 2093.09);
ACTH clip 18-39 ([M +H]+ 2465.20); somatostatin 28
([M +H]+ 1347.47) (Bruker Daltonics). Mass spectra
were acquired in an automatic mode using the Auto-
Xecute™ module of the FlexControl™ software (version
2.4, Bruker Daltonics) and using the three most abun-
dant peptide signals of the corresponding peptide mass
fingerprint and peptide fragmentation fingerprint spec-
tra. Spectra were analyzed using the FlexAnalysis™ soft-
ware (version 2.4, Bruker Daltonics). The Swiss-Prot
database (download 2005) employing the MASCOT pro-
gram (version 2.0, in-house server, Matrix Science, Boston,
MA, USA) was used to search for peptide masses to iden-
tify proteins. Database searches were performed taking into
account carbamidomethyl modification of cysteines and
possible oxidation of methionine. One missed cleavage was
allowed. A mass inaccuracy of ≤100 ppm was allowed for
the peptide mass fingerprint. For the peptide fragmentation
fingerprint, a mass inaccuracy of ≤70 ppm was allowed for
both peptide masses and their fragments. Identified pro-
teins were sent to the Proteinscape™ database (version 1.3,
Protagen, Dortmund, Germany) and checked individually
for further consideration.
Clinical chemistry measurements of C-reactive protein,
haptoglobin and hemopexin
Serum C-reactive protein (CRP), haptoglobin and hemo-
pexin concentrations were determined by quantitative
immunoassays using standard operating procedures of
the Institute of Clinical Chemistry at the University of
Regensburg, Germany.
Sputum C-reactive protein measurements
Samples were collected from healthy volunteers at the
Biomedical Research Center of Uppsala University,
Sweden (Laboratory of Dr Lars Baltzer). The volunteers
had rinsed their mouth with water 10 minutes before
collection and had not eaten within 1 h before sample
collection. The samples were immediately frozen and
then stored at -20°C.
Saliva samples were thawed at room temperature and
centrifuged prior to analysis. A standard curve with
human CRP spiked in 0.05% bovine serum albumin was
prepared at a concentration range of 0 to 5,000 pg/ml,
which is within the range of interest for CRP measure-ments in saliva (Additional file 2: Figure S1A; samples in
triplicates). Here the level of the blank samples (no CRP)
was 0.065. Measurement of the samples from healthy
volunteers resulted in a response of 0.070 and 0.075, re-
spectively (triplicates). In addition, a standard curve with
human CRP, 5,000 to 0 pg/ml spiked in saliva (4× di-
luted), was also prepared (Additional file 2: Figure S1B;
samples in triplicates).
Human hepatocyte studies
The publicly available Japanese Toxicogenomics Project
data set was used [13] and analyzed with respect to
serum DILI biomarker candidates identified in the
present study.
Statistical analysis
Statistical analysis was done with GraphPad Version 5.0
and SPSS software version 17 using a non-parametric
testing strategy. Furthermore, the MAS5 algorithm for
generating expression summaries and the Bioconductor
R package were used for the analysis of the publicly
available database (see above human hepatocyte studies
and [13]). For individual genes the ratio of control versus
treatment was determined. ANOVA was done using the
aov function in the stats package of R, and box plots
were drawn with R. Statistically significant changes are
marked with asterisks in the figures.
Results
Alanine transaminase activity in response to APAP
treatment
The mean ALT activity of healthy volunteers prior to
APAP and/or placebo treatment is depicted in Figure 1A
and was within normal range (median = 30) amongst all
study participants. Doses of 4 g APAP daily for 7 days
caused a ≥4-fold increases in ALT activity in about one-
third of study participants (Figure 1A; median = 120).
The increase in ALT was transient and returned to nor-
mal shortly after drug removal and none of the partici-
pating study subjects experienced severe liver injury.
Study subjects were divided into ‘DILI responders’ with
significantly increased ALT and ‘DILI non-responders’ in
whom ALT activity remained normal after repeated
APAP treatment.
Differentially expressed proteins in native serum of
DILI-responders prior to APAP treatment
A thiourea-containing lysis buffer was used to extract
proteins from serum as recently described [14]. As high-
abundant serum proteins such as albumin and immuno-
globulins may interfere with the separation of complex
protein mixtures, extracts from native and albumin-
depleted serum were prepared and separated by two-
dimensional electrophoresis (Figure 2). Two-dimensional
Figure 1 Serum alanine transaminase activity, CRP and haptoglobin prior to and after treatment of healthy subjects receiving 4 g of
acetaminophen daily for 7 days. (A) Serum alanine transaminase activity (ALT) prior to and after APAP treatment of healthy subjects for 7 days.
Depicted are ALT activities of DILI-responders versus non-responders receiving the same APAP dose. ALT activity in placebo-treated healthy
volunteers is also shown. Note that the ALT activity was unchanged between pre-treatment and day 1 measurements. (B) CRP serum concentra-
tion of DILI responders with either high CRP (n = 3 healthy individuals) or all DILI responders, DILI non-responders and placebo-treated healthy
subjects at baseline, day 1 and day 7 of APAP treatment. CRP measurements combined for day 1 and day 7 are also shown. (C) Haptoglobin
serum concentration of DILI responders with either high haptoglobin (n = 3 healthy individuals) or all DILI responders, DILI non-responders and
placebo-treated healthy subjects at baseline (day =0), day 1 and day 7 of APAP treatment. Haptoglobin measurements combined for day 1 and
day 7 are also shown. ***P < 0.001; **P < 0.01; *P < 0.050; ns, not significant.
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to 7 and subsequently visualized with the CCB stain. A
detailed description of the workflow, including protein
extraction, two-dimensional gel electrophoresis, image
processing, spot-cutting, trypsin in-gel digestion and
MALDI-TOF/TOF mass spectrometry of proteins, is given
in Additional file 3.
Six proteins were identified as differentially expressed
in DILI responders prior to APAP treatment (Figure 3A).
However, only haptoglobin isoforms, retinol binding
protein (RBP)4 and CRP (Figures 1B and 3B) reached
statistical significance. Remarkably, RBP expression washigher in non-responders while CRP and haptoglobin
expression was higher in DILI responders. The serum
concentrations of CRP, haptoglobin and hemopexin
were additionally analyzed by immunoassay. The base-
line CRP serum concentrations in 3 out of 12 ALT re-
sponders was 27 mg/dl and thus nearly three-fold above
ULN (Figure 1B), while the overall mean for all ALT re-
sponders was close to the upper limit of normal, that is,
10 mg/l When CRP baseline measurements for all DILI
responders were compared to the placebo arm of the
study a likewise statistically significant six-fold increase
was determined. However, CRP serum concentration did
Figure 2 Two-dimensional gel electrophoresis of serum proteins of healthy subjects receiving 4 g of acetaminophen daily for 7 days.
(A) Native serum of healthy volunteers or (B) after immunodepletion of high abundant proteins, such as serum albumin (1) and immunoglobulin
G (4). An improved resolution of apolipoprotein H (2) and apolipoprotein E (3) and haptoglobin (5) was achieved in depleted sera.
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Thus, CRP measurements were combined within study
groups. A statistically significant difference was deter-
mined for the comparison of all DILI responders versus
non-responders (Figure 1B); CRP serum concentrations
and ALT activity appeared to be correlated (Additional
file 4). Additional file 2 informs on CRP measurements
in saliva to demonstrate its facile monitoring by non-
invasive means.
Haptoglobin serum concentrations were also deter-
mined by immunoassay but the employed assay can not
distinguish between various isoforms. As depicted in
Figure 1C, the haptoglobin baseline was significantly
higher in DILI responders when compared with non-
responders or study subjects receiving placebo. Of note,
two individuals with slightly above normal CRP baseline
values also presented higher haptoglobin serum concen-
trations. Removing these individuals from the data ana-
lysis did not change the statistical significance. No
obvious treatment effect on haptoglobin serum concen-
tration was observed. Thus, haptoglobin measurements
for day 1 and 7 were combined; a statistically significant
difference for all DILI responders compared with non-
responders was determined.
Based on two-dimensional electrophoresis mass spec-
trometry, up-regulation of other serum acute phase
reactant and inflammation markers was identified,
including serum amyloid A4, alpha-1 antiproteinase
(A1AT), haptoglobin isoforms as well as kininogen.
Conversely, immunoglobulin gamma-1 chain C region
(IGHG1) and RBP4 were reduced in expression after
APAP treatment for 7 days (Figure 3C). Likewise, signifi-
cant up-regulation of adenosine deaminase (ADA) but
reduced expression of apolipoprotein (Apo)A-I, ApoH,
plasminogen and sulfidequinine oxidoreductase were
observed in DILI responders after repeated APAPtreatment. Prominent examples of regulated proteins are
depicted in Figure 3A.
Differentially expressed proteins in albumin and
immunoglobulin-depleted serum of DILI responders after
APAP treatment
To further search for regulated proteins, the high abun-
dance serum proteins albumin and immunoglobulin were
removed by the use of the SpinTrap column technology.
Efficient immunodepletion of high abundant proteins was
achieved as determined by two-dimensional gel electro-
phoresis (Figure 2). Similar to un-fractionated sera of
APAP-treated healthy volunteers, A1AT was significantly
up-regulated while haptoglobin, serum amyloid A4 and
transthyretin were down-regulated. Moreover, induced ex-
pression of ApoA1, A4, C-II and E and, after removal of
albumin, regulation of ceruloplasmin, deoxyribonuclease-
2-alpha and hemopexin were observed in APAP-treated
healthy volunteers.
Correlation between ALT activities and expression of
acute phase reactants prior to and after APAP treatment
Amongst the acute phase reactants, haptoglobin
isoforms were chosen and found to correlate with ALT
activities of individual study subjects. The relative spot
intensities of three major isoforms, denoted as spots A,
B and C in Figure 4, from individual DILI responders
correlated with ALT activity in response to APAP treat-
ment. Similar correlations were observed with other
acute phase reactants (data not shown).
Overall, 20 proteins were identified as regulated in sera
of healthy volunteers treated with APAP. Of these,
four were regulated in common in native and albumin-
depleted sera - A1AT, ApoA-I, transthyretin and haptoglo-
bin. In native sera of APAP-treated healthy volunteers
plasminogen, RBP4, beta-2-glycoprotein 1 (ApoH), ADA,
Figure 3 (See legend on next page.)
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Figure 3 Sections of two-dimensional electrophoresis gels showing regulated serum proteins from healthy volunteers. (A) ALT
responders, ALT non-responders, placebo prior to APAP or placebo treatment (day 0, left panel, I) and after daily APAP treatment for 7 days
(right panel, II). A1AT, alpha-1-antiproteinase; ApoA1, apolipoprotein A-I; Hpt, haptoglobin; TTR, transthyretin; RBP4, retinol binding protein 4;
ApoH, apolipoprotein H. (B) Results from densitometric scans of two-dimensional electrophoresis images of serum proteins regulated in DILI
responders, non-responders and placebo-treated healthy volunteers prior to APAP treatment. (C) Results from densitometric scans of two-
dimensional electrophoresis images of serum proteins regulated in DILI responders, non-responders and placebo-treated healthy volunteers after
APAP treatment for 7 days. (D) Results from densitometric scans of two-dimensional electrophoresis images of serum proteins after immunodep-
letion of high abundance proteins in DILI responders, non-responders and placebo-treated healthy volunteers after APAP treatment for 7 days.
***P < 0.001; **P < 0.01; *P < 0.05.
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and sulfide quinone oxidoreductase were regulated. Re-
moval of albumin identified either regulated or de novo
expressed serum proteins, that is, the ApoA-IV, C-II and E
as well as ceruloplasmin, deoxyribonuclease-2-alpha and
hemopexin. These findings document the importance of
comparative proteomic studies (Figure 5A). Addition-
ally, the results of the present study were compared
with published data of serum proteomic profiling in pa-
tients with non-alcoholic steatohepatitis or DILI. This
revealed 10 proteins as uniquely associated with APAP-
induced liver injury (AILI) prior or in response to drugFigure 4 Isoforms of haptoglobin identified as regulated in healthy v
electrophoresis showing three major isoforms of haptoglobin. (II) Results o
serum proteins regulated in DILI responders, non-responders and placebo-
days. (III) Correlation of serum ALT activities and haptoglobin isoforms in D
*P < 0.05.treatment in healthy subjects (Figure 5B; Additional
file 5).
Human hepatocyte studies
Publicly available data were retrieved [13] and analyzed
for drugs labeled as either no- (n = 8), low- (n = 45) or
most-DILI-concern (n = 39). This confirmed regulation
of newly identified serum biomarkers of DILI suscepti-
bility at the transcript level for a wide range of idiosyn-
cratic agents and suggests a role of acute phase reactants
in different mechanisms of liver injury (Figure 6 and
Additional file 6).olunteers prior to APAP treatment. (I) Two-dimensional gel
f densitometric scans of two-dimensional electrophoresis images of
treated healthy volunteers prior to and after APAP treatment for 7
ILI responders after APAP treatment for 7 days. ***P < 0.001; **P < 0.01;
Figure 5 Regulation of serum proteins in DILI and other liver
diseases. (A) Venn diagram of regulated proteins in native (left
circle) and albumin-depleted (right circle) sera of DILI responders.
Four proteins were common amongst native and albumin- and
IgG-depleted sera. (B) Venn diagram of the findings of the present
study with reports for patients diagnosed with mild, moderate and
severe DILI and/or non-alcoholic steatohepatitis (NASH) [20,23].
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AILI is a prominent cause of ALF in the US; it can
primarily be attributed to unintentional as well as
intentional ingestion of above therapeutic doses [15].
However, 7% of acute liver failures are at therapeutic
doses, as reported by the acute liver failure group, who
determined the incidence, risk factors, and outcomes of
APAP-induced ALF at 22 tertiary care centers in the
United States. As APAP serum concentrations in cases
of ALF at therapeutic APAP doses were similar to those
in overdose patients and the median APAP concentra-
tion differed by only a factor of two (14. 5 μg/dL versus
31 μg/dL), one might possibly suggest self-reported
doses and time of ingestion to be unreliable. The sem-
inal study of Larson et al. [15] reported a dramatic in-
crease in APAP-induced ALF particularly in patients
with chronic pain and co-medications (narcotics and/or
depressants) as well as alcohol abuse. Thus, identifying
biomarkers that would predict individuals at risk for
AILI prior to drug treatment would greatly improve
drug safety. For this purpose the serum proteome ofhealthy subjects was analyzed prior to and after treat-
ment with the maximum acceptable dose for APAP
given in quarterly portions per day for 7 days. This iden-
tified important pre-treatment serum protein associa-
tions in individuals that subsequently developed liver
injury upon drug treatment.Regulation of acute phase proteins in AILI responders
A significant difference in expression of serum markers
of inflammation was observed in AILI responders versus
non-responders. Of the various positive and negative
acute phase reactants, CRP, haptoglobin, ApoA-I, beta-2
glycoprotein 1 (ApoH) and RBP are important pre-
treatment associations. The mean CRP in 3 out of 12
DILI susceptible subjects was nearly 3-fold higher than
the normal upper limit, possibly indicating a mild pre-
existing inflammation even though active inflammation
of the liver would be associated with CRP levels well
above 100 mg/L. Nonetheless, all subjects entering the
study were vigorously tested and ALT as well as all other
laboratory parameters were within normal ranges. While
pre-dose CRP serum concentrations were significantly
elevated in ALT responders, its expression was basically
unchanged after 7 days of treatment. Notably, CRP
serum concentrations and peak ALT measurements ap-
pear to correlate (Additional file 4). It is of considerable
importance that CRP stimulates phagocytosis of Kupffer
cells but decreases their TNF production in a complex
manner in which various Fc receptors are involved [16].
A further biomarker for DILI susceptibility is hapto-
globin. This positive acute phase reactant functions as a
protective anti-oxidant [17] and plays a role in the retic-
uloendothelial system. This system is composed of
monocytes and macrophages and is part of the immune
system to remove cell debris as observed in cytolitic
hepatitis. Haptoglobin binds hemoglobin and plays a
crucial role in heme iron recovery to prevent its loss
and to protect kidneys from damage by renal iron
loading [18]. Prior to APAP treatment, haptoglobin
isoforms with different pI but similar Mr (<20 kDa) were
significantly (P < 0.01) up-regulated in ALT responders
(Figures 3C and 4). Of note, the isoforms remained sig-
nificantly up-regulated after repeated APAP treatment
for 7 days. Diverse functions have been attributed to this
tetrameric glycoprotein, with recent evidence pointing to
a function as a chemo-attractant for macrophages [19].
Haptoglobin deficiency is associated with attenuation
of hepatosteatosis and impairment of glucose homeosta-
sis, suggesting this protein has a wider role in liver in-
jury. Because of haptoglobin’s role in iron metabolism,
the expression of hemopexin was studied as well but
remained unchanged in all of the study groups investi-
gated (Additional file 7).
Figure 6 Box plots of gene expression changes after treatment of cultures of human hepatocytes with drugs labeled as no-, less- or
most-DILI-concern. (A) Serum amyloid. (B) Sulfide quinone oxidoreductase. (C) Apolipoprotein C2. (D) Ceruloplasmin. Box blots marked with a
star are statistically significant at P < 0.05. Cultures of human hepatocytes were treated with drugs labeled as either no- (n = 8), low- (n = 45) or
most-DILI-concern (n = 39) for 2 and 24 h, respectively. A full list of drugs used is given in Additional file 6.
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regulated and included the acute phase reactant A1AT
in native and albumin-depleted sera of ALT responders.
This serpin is mainly produced by the liver and irrevers-
ibly inhibits trypsin, chymotrypsin and plasminogen
activator. In DILI patients the serum concentration of
alpha-1-antitrypsin and activity of the transaminases
ALT and aspartate aminotransferase (AST) are signifi-
cantly correlated [20]; however, A1AT serum concentra-
tions are reduced in ALF [21]. Infantile liver cirrhosis is
linked to carriers of the homozygous allele Z or M-
Malton of the A1AT gene [22] while the Pittsburgh vari-
ant causes hemorrhagic diathesis.
Another major acute phase reactant significantly up-
regulated in AILI susceptible subjects is serum amyloid
A (SAA). During an acute phase response this protein is
rapidly synthesized by the liver; its expression is regu-
lated by IL-1, IL-6 and TNFα. SAA is an apolipoprotein
(apoSAA) associated with high-density lipoprotein and
together with CRP are sensitive markers for inflamma-
tion. In DILI patients SAA proteins are significantly
regulated; a positive correlation between alkaline phos-
phatase activity and expression of serum amyloid A2
(isoform a) has been reported [23].
Conversely, APAP treatment caused significant down-
regulation of the negative acute phase reactant transthy-
retin in AILI responders. This triiodothyroxine binding
protein is referred to as pre-albumin and is significantly
regulated in inflammation. Transthyretin interacts with
RBP and was reported as significantly regulated in DILI
[23] and non-alcoholic fatty liver disease (NAFLD) pa-
tients of different types [20]. It was also shown to be ini-
tially repressed but subsequently up-regulated by more
than six-fold in sera of APAP-treated rats after 6 and 24
h, respectively [24].
About 40% of plasma transthyretin circulates as a com-
plex with RBP. This protein is another negative acute
phase reactant and a member of the lipocalin family; the
complex stabilizes the binding of retinol to RBP to de-
crease its glomerular filtration and renal catabolism.
Importantly, RBP was significantly down-regulated in
ALT responders amongst APAP-treated healthy volun-
teers; a similar two-fold down-regulation was reported
for APAP-treated rats [24]. Independent studies with
DILI and NAFLD patients observed similar regulation
of RBP [20,23].
A further acute phase reactant regulated in albumin-
depleted sera of ALT responders is ceruloplasmin. This
multicopper oxidase plays an important role in oxygen
detoxification and is up-regulated during inflammation
and hyperoxia [25]. The enzyme oxidizes Fe2+ to Fe3+
without release of radical oxygen species. It is involved
in iron transport across the cell membrane. Ceruloplas-
min is synthesized by the liver and secreted into plasmaby hepatic stellate cells as well as Kupffer cells [26]. In
Morbus Wilson patients ceruloplasmin serum levels are
decreased.
Drug-induced liver inflammation and immune response
Of particular interest is ADA, which is expressed in all
tissues and in large amounts of T lymphocytes. Expres-
sion of this enzyme was significantly up-regulated in
native serum of ALT responders after 7 days of APAP
treatment. The release of ADA into serum documents
cellular damage in response to APAP treatment. An im-
portant function of serum ADA is the conversion of ad-
enosine to the nucleoside inosine, which is unable to
bind to adenosine receptors, thereby influencing neutro-
phil degranulation, blood flow and oxygen consumption.
It is tempting to speculate that increased serum ADA re-
sults in the production of anti-inflammatory molecules
similar to those seen with non-selective adenosine recep-
tor antagonists, that is, xanthine derivatives. Lack of
ADA causes immunodeficiency and knockout mice die
perinatally due to severe liver cell degeneration [27,28].
ADA deficiency is also associated with hyperbilirubi-
nemia and hepatitis but can be resolved by ADA re-
placement therapy [29]. In acute infective hepatitis
serum ADA levels increase; a positive correlation be-
tween serum ADA and total bilirubin was reported [30].
This positive correlation may suggest bilirubin functions
as an anti-oxidant [31].
In DILI responders and after repeated APAP treatment
IGHG1 was significantly reduced. Importantly, immuno-
allergic DILI is associated with idiosyncratic liver injury.
While reactive metabolites may function as haptens, the
parent drug may also elicit an autoimmune reaction with
the production of anti-drug antibodies. Usually, during
immunoallergic DILI IgG levels are increased and auto-
antibodies against liver-specific and non-liver-specific
antigens are detected. Possibly, the observed reduction
of IGHG1 in AILI susceptibility is due to glutathione de-
pletion in lymphocytes as suggested by Spielberg and
Gordon [32].
Inflammation and coagulation homeostasis in
drug-induced liver injury
The complex interplay between drug-induced inflamma-
tion and coagulation homeostasis is the subject of in-
tense research. Synthesized in the liver, plasminogen is
converted into plasmin by plasminogen activators and
bound to fibrin. Plasmin dissolves fibrin of blood clots
and acts as a proteolytic factor in a variety of biological
processes, including inflammation. It is activated by the
urokinase-type plasminogen activator, collagenases and
several complement zymogens, such as C1 and C5. It is
inactivated by alpha-2-antiplasmin immediately after dis-
sociation from the clot. Importantly, plasminogen serum
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tible patients after 7 days of APAP treatment. Several re-
ports describe a role of plasminogen in macrophage
accumulation during liver repair [33]; plasminogen ap-
pears to be essential for neutrophils to accumulate at the
border of damaged liver tissue to facilitate repair events
[34]. Treatment of mice with APAP caused activation of
the coagulation system and protease-activated receptor
signaling to contribute to liver injury [35]. Furthermore,
fibrin deposition aggravated liver injury; however, plas-
minogen deficiency reduced APAP liver injury [36] as ob-
served in plasminogen-deficient mice and wild-type mice
treated with tranexamic acid, an inhibitor of plasminogen
activation. In the present study serum plasminogen con-
centrations of AILI responders were statistically signifi-
cantly reduced, therefore demonstrating clinical relevance
of the animal findings. Equally, serum plasminogen con-
centrations were reduced in APAP-treated non-ALT re-
sponders, reinforcing the notion that plasminogen is
involved in the fine-tuning of liver regeneration after AILI.
Significant down-regulation of kininogen-1 in serum
of ALT responders was another finding. This protein
functions as a thiol protease inhibitor. High molecular
weight kininogen (HMWK) plays an important role in
blood coagulation and inflammation and functions as a
precursor of kinin, which is part of the vasoactive kinin-
kallikrein system. Kininogens also inhibit the thrombin-
and plasmin-induced aggregation of thrombocytes and
are therefore antithrombotic proteins. Specifically, kinin-
ogen is a mediator of inflammation and causes increased
vascular permeability, stimulation of nociceptors, release
of mediators of inflammation (that is, prostaglandins)
and excerts cardioprotective effects (directly via bradyki-
nin action, indirectly via endothelium-derived relaxing
factor action).
The complex interplay between collagen, high molecu-
lar weight kininogen (HMWK), prekallikrein and factor
12 (Hagemann factor) results in a primary scar. Initially
synthesized in the liver, prekallikrein is converted to kal-
likrein by factor 12 and eventually cleaves HMWK to re-
lease bradykinin. In a study by Cordova and colleagues
[37] the activities of the Hagemann factor, HMWK and
prekallikrein were reduced and dependent on the degree
of liver failure. Equally, plasma kallikrein clearance was
markedly reduced in APAP intoxicated rat livers [38].
The observed reduction of HMWK in DILI responders
is likely the result of APAP poisoning of hepatocytes.
Regulation of serum apolipoproteins in drug-induced
liver injury
The emerging role of lipoproteins in inflammation and
cellular signaling is the subject of intense research [39].
Serum proteome profiling of healthy volunteers revealed
a significant three-fold down-regulation of ApoA-I inALT responders after repeated APAP treatment. This
protein participates in the reverse transport of choles-
terol from tissues to the liver, thereby promoting choles-
terol efflux. It functions as a cofactor for the lecithin
cholesterol acyltransferase and is a major protein of
plasma HDL, typically found in chylomicrons.
ApoA1 expression was negatively correlated with total
bilirubin in a patient cohort diagnosed with DILI [23].
These investigators also observed significant regulation
of ApoA2, A4 and A4 precursor in NAFLD and various
degrees of liver fibrosis. In contrast, ApoC-II was signifi-
cantly up-regulated in albumin-depleted sera of ALT re-
sponders. This protein is part of the very low density
lipoprotein (VLDL) particle. The association of ApoC2
with plasma chylomicrons, VLDL and HDL is reversible
and functions in the secretion and catabolism of
triglyceride-rich lipoproteins. Levels of the related
ApoC-III were likewise significantly changed in patients
diagnosed with DILI as were ApoC1 levels in serum of
patients diagnosed with NAFLD [20].
Furthermore, ApoE expression was more than four-
fold up-regulated in DILI responders upon APAP treat-
ment. This lipoprotein mediates binding, internalization
and catabolism of lipoprotein particles and serves as a
ligand for the ApoE-recognizing receptor of hepatic tis-
sues. Its expression was reported as significantly up-
regulated in serum of patients diagnosed with DILI but
not in those with non-alcoholic steatohepatitis [20,23].
Early work had shown transcriptional and posttranscrip-
tional regulation of ApoE, ApoA1 and ApoA2 in liver
tissue at various pathophysiological states [40] and
changes in lipoprotein binding and uptake by hepato-
cytes during rat liver regeneration [41]. In a proteomic
investigation of drug-induced steatosis a moderate but
statistically significant up-regulation of ApoE was ob-
served in rat liver, further documenting its prognostic
value in predicting DILI. Additionally, DeKroon and co-
workers reported an anti-apoptotic role of ApoE [42],
while others reported that ApoE protects against severe
liver disease in hepatitis C virus infection [43].
Conversely, ApoH was significantly down-regulated in
ALT responders after APAP treatment. This protein is
synthesized by the liver and secreted in plasma, associ-
ates with heparin and dextran sulfate and may prevent
activation of the intrinsic blood coagulation cascade by
binding to phospholipids on the surface of damaged
cells. ApoH was also significantly regulated in rat serum
after APAP exposure [24].
Deoxyribonuclease-2-alpha protein was uniquely
down-regulated in response to APAP treatment. This
protein hydrolyzes DNA with preference for double-
stranded DNA and plays a major role in the degradation
of nuclear DNA in cellular apoptosis during develop-
ment. Its lysosomal localization and its known role in
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phagocytosis suggest an interplay of this protein with
Kupffer cells in AILI. The reduced expression of this
protein may be part of the fine tuning of liver regener-
ation in response to APAP treatment.
Finally, in DILI responders sulfide:quinone oxidore-
ductase was significantly regulated. This mitochondrial
enzyme was shown to catalyze the oxidation of hydrogen
sulfide and belongs to the SQRD family of proteins [44].
It is tempting to speculate that this protein is involved
in the metabolism of glutathione (GSH) or cysteine con-
jugates of APAP metabolites.
The following caveats need to be considered. First, the
study is based on APAP given to healthy individuals and
although robust statistical relationships were deter-
mined, further studies are required so that the findings
can be extrapolated to other types of DILI in terms of
molecular mechanisms and clinical features. Second, the
drugs tested in hepatocyte cultures are idiosyncratic
agents; nonetheless, the mechanisms of liver injury may
differ amongst them. While transcript regulation of
serum acute phase reactants could be demonstrated for
a wide range of drugs and by comparison with published
serum proteome profiling in DILI patients, additional
studies are needed to confirm the results obtained after
APAP treatment.
Conclusions
Several serum biomarkers for AILI were identified that
may be of utility for other drugs with risk for DILI, thus
providing opportunities for drug development programs
to improve patient safety.
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